Upadacitinib and high-dose dexamethasone for new immune thrombocytopenia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests the combination of upadacitinib (an immune-modulating drug) and high-dose dexamethasone (a steroid) as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). The goal is to see if this combination can raise your platelet count and reduce bleeding better than usual care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been recently diagnosed with ITP and not yet had treatment for it.
- Your platelet count must be very low (below 30,000) or moderately low (below 50,000) with significant bleeding symptoms.
- You cannot have taken any other ITP treatments before joining, such as steroids or stronger immune-suppressing drugs.
- You cannot have HIV, hepatitis B or C, or an active infection.
- You cannot have cancer or other serious medical conditions like heart disease, lung disease, kidney problems, or other autoimmune diseases.
- You cannot be pregnant or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a substance called NAD can help adults with immune thrombocytopenia (ITP) whose platelet levels stay low even after standard treatments. ITP is a condition where the immune system attacks platelets, causing easy bruising and bleeding. The study aims to see if NAD can safely raise platelet counts.
This study tests whether adding another medicine (telitacicept) to a standard platelet-boosting drug (eltrombopag) works better than eltrombopag alone for adults with ITP that hasn't improved with steroids. The goal is to help raise your platelet counts and reduce bleeding risk.
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
This trial tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with long-term immune thrombocytopenia (ITP) who have already tried steroids without lasting success.
This study tests different doses of a drug called zanubrutinib (a BTK inhibitor) to find the best dose for adults with newly diagnosed ITP that hasn't been treated yet. It aims to see if this drug can safely boost platelet counts and reduce bleeding symptoms.
This trial tests if adding teriflunomide to high-dose dexamethasone helps adults newly diagnosed with immune thrombocytopenia (ITP) who have low platelets or bleeding. It aims to find a safer, more effective way to raise platelet counts.
Hear when a new Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.